Summary. Platelet-activating factor (PAF) stimulated mouse spleen cells to release soluble factors (termed S2 factors) which were capable of inducing increased rosette inhibition titres when applied to fresh mouse spleen cells in the rosette inhibition assay. In this ability the S2 factors mimic that of pregnancy serum, an action previously ascribed to 'early pregnancy factor'. The PAF-stimulated production of these S2 factors was not influenced by inhibitors of cyclooxygenase metabolism, but was completely inhibited by the lipoxygenase inhibitors, diethyl carbamazine and nordihydroguaiaretic acid. The S2 factors had a lipid-like character in that they were extractable in organic solvents. The calcium ionophore A23187 also stimulated the production of these factors which may well be products of the lipoxygenase pathway of arachidonic acid metabolism.
Introduction
Orozco et al. (1990) extended their studies (Orozco et ai, 1986) on the link between plateletactivating factor (PAF) and expression of activity of'early pregnancy factor' (EPF) by demonstrat¬ ing that a combination of PAF and sera from mice in oestrus could mimic the action of pregnancy sera by inducing an elevated rosette inhibition titre (RIT) when applied to mouse spleen cells in vitro. Neither component could induce this effect if applied to cells alone, the combination was required. PAF stimulated the spleen cells to release soluble factors (termed S2 factors) which were themselves capable of inducing elevated RITs if applied to fresh spleen cells even in the absence of serum from oestrous mice. However, the PAF-stimulated cells were rendered refractory to the action of these S2 factors and failed to display elevated RIT values unless oestrous mouse serum was also added, the serum components acting to reverse the refractory state. The discovery of these PAF-induced S2 factors which are directly active in the rosette inhibition assay is an important and germinal observation as their identification could contribute greatly to our understanding not only of the mechanism of action of PAF but also that of the so-called 'early pregnancy factor' in the rosette inhibition assay.
The observed potency of the S2 factors coupled with the known primary action of PAF to stimulate arachidonic acid metabolism in a wide variety of cell types (Snyder, 1985; Kawaguchi & Yasuda, 1984; Chilton et ai, 1984; Macconi et ai, 1985) led us to investigate whether arachidonic acid metabolites generated via the cyclooxygenase and/or lipoxygenase pathways are involved in the generation of the S2 factors.
Materials and Methods PAF. Synthetic PAF (l-0-octadecyl-2-acetyl-j«-glycero-3-phosphocholine) was obtained from Boehringer (Mannheim, FRG) and prepared and used as previously described (Orozco et al, 1990 (1990) .
Extraction of the S2 fraction. S2 fractions prepared as described above were subjected to the two step extraction procedure of Clancy & Hughli (1983) . The first extraction step separates total lipids from substances such as proteins and buffer salts, while the second step performed on the initial total lipid fraction separates polar from less polar lipids. In the first step the S2 fractions was combined with isopropanol and 5 M-formic acid in the ratio 10:0-5:003 (by vol.). After 5 min, 1-5 volumes of ether were added, resulting in the development of two phases. The upper organic phase consisting of an isopropanol/ether mixture was removed and combined with 10n-NH4OH in a ratio of 20: 0015 (v/v). This was evaporated to dryness under a stream of N2. For the second extraction step, the residue was dissolved in 0-5ml chloroform:methanol (1:1, v/v) and 0-22 ml 10mM-NH4OH was added, resulting in a two-phase separation. The upper aqueous methanol and the lower chloroform phases were collected and dried under a stream of nitrogen. The residues were resuspended in 20 µ (per 200 µ original S2 fraction) 65% methanol, 0-1% acetic acid, pH 5-6 (with NH3). Then 10 µ aliquants of 10-fold serial dilutions prepared in PBS/BSA (0-2 mg/ml) were taken for testing in the rosette inhibition assay.
Other methods. Collection of sera and preparation of spleen cells were performed as described previously (Orozco et al. 1986 ).
Results
Effect of cyclooxygenase and lipoxygenase pathway inhibitors on generation of S 2 factors When PAF-stimulated mouse spleen cells were reincubated in PBS after PAF treatment, a soluble fraction (S2) was generated which was extremely potent in inducing an elevated RIT when applied to fresh mouse spleen cells see (Orozco et ai, 1990; and Fig. la) . If the mouse spleen cells were treated with the cyclooxygenase inhibitors aspirin and indomethacin before PAF stimulation, then there was little or no effect on the ability of these cells to generate an active S2 fraction (Fig. lb) . On the other hand if the cells were treated with the lipoxygenase pathway inhibitors, diethyl¬ carbamazine (Mathews & Murphy, 1982) or nordihydroguaiaretic acid (Salari et ai, 1984) before PAF stimulation, the ability to produce an active S2 fraction was completely abolished (Fig. la) , indicating that the PAF-stimulated generation of the S2 factors was dependent upon the activity of the lipoxygenase pathway of arachidonic acid metabolism. 
Lipid extraction of S2 factors
When the S2 fraction generated from PAF-stimulated cells was extracted by the two-step pro¬ cedure of Clancy & Hughli (1983) , essentially all of the S2 factor activity was extracted with the total lipid fraction into the isopropanol/ether phase (Fig. 2) . Subsequent fractionation of this total lipid extract into polar and less polar fractions by the second step of the procedure resulted in a partitioning of S2 factor activity between both phases. While the bulk of the activity partitioned with the more polar lipids into the aqueous methanol phase, a significant activity was still associated with the less polar lipid fraction in the chloroform phase (Fig. 2) .
Calcium ionophore stimulation of production of S2 factors As shown in Fig. 3 (Snyder, 1985) . The primary mode of action of PAF, however, on almost all cell types appears to be via stimulation of phosphatidylinositol turnover leading to activation of phospholipase C and mobilization of Ca2+ ions (Shukla & Hanahan, 1983; Mauco et ai, 1983; Kawaguchi & Yasuda, 1984) . A common consequence is the activation of phospholipase A2 and stimulation of arachidonic acid metabolism which may lead to eicosanoid production via the cyclooxygenase and/or lipoxygenase pathways (Shaw et ai, 1981; Chilton et ai, 1982; Roubin et ai, 1983; Kawaguchi & Yasuda, 1984) . The present studies explored the possible involvement of these pathways in S2 factor production. The results of the inhibitor studies strongly implicated the lipoxygenase pathway. Specific inhibitors of the cyclooxygenase pathway, aspirin and indometha¬ cin, had little or no influence on the PAF-stimulated production of S2 factors. The lipoxygenase pathway inhibitors, diethylcarbamazine and nordihydroguaiaretic acid, however, completely blocked the production of these factors, indicating that activation of this pathway of arachidonic acid metabolism was necessary for the generation of these factors. The extraction studies per¬ formed on the S2 fraction indicated that the S2 factors were not only dependent on the lipoxy¬ genase pathway but may well be products ofthat pathway. Their extraction into the organic phase indicating a lipid-like character and their extreme potency described in this and the previous paper would be consistent with this interpretation. Because diethylcarbamazine and nordihydroguaiare¬ tic acid inhibit the initial steps in the lipoxygenase pathway, the conversion of arachidonic acid to 5-hydroperoxyeicosatetraenoic acid and subsequently to leukotriene A4 (Mathews & Murphy, 1982; Salari et ai, 1984) , a range of lipoxygenase products, including LTB4, 5-hydroxyeicosatetraenoic acid (5-HETE) and the peptidoleukotrienes, LTC4, LTD4 and LTE4 for example, must be con¬ sidered as possible candidates. As the bulk of the S2 factor activity extracts into the polar aqueous methanol phase during the second step of the Clancy & Hughli (1983) procedure, it may be that activity expression is associated with the more polar leukotrienes such as the peptidoleukotrienes which are known (Clancy & Hughli, 1983) to extract preferentially into this phase. LTB4, and particularly 5-HETE, preferentially extract into the chloroform phase, but this phase still displays some activity. Given that the partitioning of these metabolites into one phase or the other is not absolute (Clancy & Hughli, 1983) and that they are all molecules with potentially potent biological activities, it is clear further characterization studies are necessary. The basic conclusions we draw at the present time are that the generation of the S2 factors is dependent on the lipoxygenase pathway, they are lipid in character, and so may possibly be lipoxygenase products.
These conclusions are supported by the fact that the calcium ionophore A23187 can also stimu¬ late the production of S2 factors. This ionophore, by raising intracellular Ca2+ levels, can activate phospholipase A2, stimulating arachidonic acid metabolism and causing many cell types to release eicosanoids, particularly lipoxygenase products. For example, it stimulates human polymorphonuclear leucocytes to release principally LTB4, LTC4 and 5-HETE (Borgeat & Samuelsson, 1979; Hansson et ai, 1981; Shak & Goldstein, 1984) . The ionophore stimulation of S2 factor production is also inhibited by diethylcarbamazine and nordihydroguaiaretic acid, indicating lipoxygenase involvement, and the activity is extracted into the organic phase. Ionophore stimulation of human polymorphonuclear leucocytes also produces lipid-extractable factors capable of inducing elevated RIT values (F. M. Clarke, unpublished) . Taken together these observations support the conclusions above as to the character and mode of production of the S2 factors.
The identity of the cells producing these factors in the spleen cell preparation is not known. There is no reason to suppose, for example, that the cell population stimulated to produce the S2 factors is that which responds to them. Indeed, it is quite probable that they are different popu¬ lations. For example, the rosette-forming cells are T-lymphocytes (Morton et ai, 1975; Rolfe et ai, 1984) , in fact a select subpopulation of T-lymphocytes, because under our assay conditions only 3% of the total spleen cell population are involved in rosette formation. The assay therefore moni¬ tors the ultimate response of only a small subpopulation of T-lymphocytes. While there is evidence that T-lymphocytes may respond to and metabolize lipoxygenase products (Rola-Pleszezynski et ai, 1982; Payan et ai, 1984; Goetzl et ai, 1988; Ödländer et ai, 1988) , there is little or no evidence that they can be stimulated to produce them (Poubelle et ai, 1987; Goodwin & Behrens, 1988) . Other leucocytes, monocytes and macrophages are known to produce eicosanoids on stimulation (Snyder, 1985) and so may be the source of S2 factors in the spleen cell preparation. It The present studies also have other implications concerning the appreciation of both the 'early pregnancy factor' phenomenon and the physiological significance of production of embryo-derived PAF. We have shown in these studies that (i) a combination of PAF and serum from oestrous mice, and (ii) PAF or ionophore-induced S2 factors can both mimic the action of pregnancy sera by inducing the expression of an elevated rosette inhibition titre. This ability or activity of pregnancy sera has long been ascribed to the presence in these sera of a so-called 'early pregnancy factor' (Morton et ai, 1976 (Morton et ai, , 1977 (Morton et ai, , 1987 . The choice of this term to describe an activity in a complex biological assay, while understandable in an historical context, has been a little unfortunate, as it implies the existence of a single, unique factor in sera responsible for this activity expression. This need not be so. As we have pointed out previously, characterization studies (Clarke et ai, 1980; Clarke & Wilson, 1985) indicate that a complex system of components is involved and so we have emphasized (Clarke & Wilson, 1985) that the basis for this activity expression may well be multifactorial. The present results serve again to emphasize this point, by demonstrating that comparable activity expression can be achieved by applying either active factors (the S2 factors), or an appro¬ priate stimulatory/regulatory system (PAF plus serum from oestrous mice). It is quite possible that pregnancy sera could contain either active factors or an appropriate stimulatory/regulatory system or both. The presence of one or both of them would allow the sera to express 'EPF' activity. An appreciation of these possibilities and therefore the likely nature of the serum 'EPF' system should help to explain and resolve the apparent complexities which currently surround the characterization of this phenomenon.
Using PAF antagonists, Spinks & O'Neill (1988) provided evidence that embryo-derived PAF activity was necessary for the establishment of pregnancy in the mouse but suggested that the mechanism by which PAF influences implantation may not be solely mediated via platelet acti¬ vation. The present results suggest that one role of PAF may be that of stimulating eicosanoid production, with these potent vasoactive agents co-operating with PAF to promote the proinflammatory reactions which precede and accompany implantation in this and other species. Malathy et ai (1986) have noted a surge in leukotriene production in the rat uterus during the periimplantation period. In addition to their proinflammatory actions, leukotrienes are also becoming recognized as potent regulators of T-lymphocyte function (Goetz et ai, 1988; Goodwin & Behrens, 1988 
